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Abstract: Cyclins play a fundamental role in the cell cycle. Recent studies have focused on their role in the
development of various malignancies. The objective of this study was to evaluate and compare the expression of
cyclins A and E in common nevi, dysplastic nevi and malignant melanomas, and to investigate the relationship
between cyclin expression and some pathological parameters such as tumor thickness, ulceration, regression,
and mitotic rate, as well as several clinical and phenotypic parameters such as skin phototype, hair and eye color,
number of nevi, personal or family melanoma history, and personal history of nonmelanoma skin cancer (NMSC).
A total of 102 melanocytic skin lesions, including 30 common nevi, 38 dysplastic nevi and 34 melanomas, were
examined. Expression of cyclins was detected by immunohistochemistry and quantified as a percentage of im-
munostained cell nuclei in each sample. Significant differences in expression of both cyclins were found between
all lesion types: the median percentage of cyclin A-positive nuclei was 8.2% in melanomas, 3.4% in dysplastic
nevi, and 0.95% in common nevi (p < 0.001). The corresponding percentages for cyclin E were 9.5%, 4.25% and
1.44% (p < 0.001). Expression of both cyclins was significantly higher among patients with a personal history of
NMSC. Cyclin A was also significantly overexpressed in patients with a high total nevus count (TNC) compared
to moderate and low TNC. Expression of cyclins did not significantly correlate with the other clinicopathologic
features investigated. These findings indicate the possible involvement of cyclins A and E in the pathogenesis of
malignant melanoma. Our results also show a potential diagnostic significance of these cyclins as markers allow-
ing discrimination between dysplastic nevi and melanoma. (Folia Histochemica et Cytobiologica 2012, Vol. 50,
No. 2, 263–269)
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Introduction
Progression through the cell cycle is controlled by
cyclins, cyclin-dependent kinases (CDK), various tran-
scription factors, suppressor gene products, and in-
hibitory proteins. Cyclin E, in conjunction with CDK2,
regulates essential processes at the G1/S boundary of
the cell cycle. Cyclin A, co-operating first with CDK2
and then with CDK1, plays a crucial role in DNA rep-
lication in the S phase and induces the cell to enter
the M phase [1].
Altered expression of cyclins A and E has been
demonstrated in different malignancies. Cyclin A
overexpression was detected in several myeloid leu-
kemia cell lines [2], and its level was also found to
correlate with astrocytoma malignancy [3]. In colorec-
tal cancer, high levels of cyclin A were associated with
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a poor prognosis [4]. A similar relationship was dem-
onstrated in non-Hodgkin’s lymphoma, non-small-cell
lung carcinoma, esophageal squamous cell carcinoma,
prostatic cancer, carcinomas of the renal pelvis and
ureter, osteosarcoma and other soft tissue and smooth
muscle tumors [5–13]. The clinical significance of cy-
clin E overexpression has been proved in laryngeal
squamous cell carcinoma, non-small cell lung cancer,
endometrial adenocarcinoma, human papilloma virus-
related cervical neoplasia, testicular germ cell tumors,
gastric and pancreatic cancer and hepatocellular car-
cinoma [14–21]. The association of cyclin E overex-
pression with tumorigenesis has also been observed in
lymphomas, acute myelogenous leukemia, chronic lym-
phocytic leukemias and osteosarcomas [10, 22–24]. The
role of cyclin E has been extensively investigated in
breast cancer; the results showed that it was not only
a factor involved in carcinogenesis, but also could be
a valuable prognostic marker and biochemical marker
of tamoxifen treatment efficacy [25].
In dermatological research, most clinical and im-
munohistochemical studies have concerned the ex-
pression of cyclin D1 and D3 in a variety of benign
and malignant tumors including melanocytic lesions.
Our previous study on expression of cyclins D1 and
D3 in melanocytic lesions demonstrated that G1/S
abnormalities were crucial for the progression of
malignant melanoma, and that enhanced cyclin D1
and D3 expression was associated with increased
melanocyte proliferation in both melanoma and dys-
plastic nevi [26]. On the other hand, the expression
of cyclins A and E in melanocytic skin lesions has been
the subject of only a few studies published to date,
and some results are discordant. In the study by Geor-
gieva et al. [27], significant overexpression of cyclin E
was observed in primary and metastatic melanomas
compared to nevi. Increased expression of cyclin E in
melanomas was also reported by Bales et al. [28] and
Tang et al. [29]. Bales et al. [30] provided evidence
that low molecular isoforms of cyclin E forms are in-
volved in the regulation of human melanoma progres-
sion and invasion. There is, however, some contro-
versy about the role of cyclin A in melanomas. Most
authors have reported its overexpression [29, 31, 32],
and some of them have suggested a strong correla-
tion of that cyclin with melanoma cell proliferation
[33, 34] and indicated its potential as a prognostic
factor for patients with superficial spreading mela-
nomas [35]. On the other hand, Georgieva et al. [27]
found very weak expression of cyclin A in melano-
mas, not different to that in nevi.
In the present study, we investigated by immuno-
histochemistry the expression of cyclins A and E in
common nevi, dysplastic nevi, and malignant mela-
nomas in correlation with (1) pathological parame-
ters, such as tumor thickness (Breslow scale), ulcer-
ation, regression, and mitotic rate, as well as (2) sev-
eral clinical and phenotypic parameters known to
correlate with the incidence of melanoma, such as skin
phototype, hair and eye color, nevus count, personal
or family melanoma history, and personal history of
nonmelanoma skin cancer.
Material and methods
Patients. Melanocytic skin lesions (n = 102) were collected
from 52 male and 50 female patients at the Department of
Dermatology, Jagiellonian University Medical College,
Krakow, Poland. The mean age of the whole group was
44.1 years (SEM ± 1.91). Melanomas were diagnosed in 17 males
and 17 females (mean age 62.1 ± 2.39 years), dysplastic nevi
in 20 males and 18 females (mean age 34.8 ± 2.88 years),
and common nevi in 15 patients of each sex (mean age 36.5 ±
± 2.88 years). The age differences between sexes were sta-
tistically insignificant. None of the patients with melanoma
had metastases. The study was approved by the Ethics Com-
mittee of the Jagiellonian University in May 2008. Written
informed consent was obtained from each patient follow-
ing the guidelines of the Helsinki Declaration.
Dermoscopy and clinical examination. The lesions were
selected for removal by dermoscopy using an Eris Medical
videodermatoscope. Surgical excision of melanocytic skin
lesions for histopathological evaluation was recommended
when the lesion showed one of the following clinical or der-
moscopic features: (1) benign nevus located in highly trau-
matic area; (2) the presence of two out of three criteria of
the three-point checklist as a screening method [36]; or (3)
the presence of one or two melanoma-specific local crite-
ria. The samples collected included 30 common nevi (com-
pound nevi — 16, intradermal nevi — 10, junctional nevi —
2, combined nevi — 2), 38 dysplastic nevi and 34 melano-
mas including nodular melanoma — 14, superficial spread-
ing melanoma — 11, lentigo maligna melanoma — 6, acral
lentiginous melanoma — 1, and undefined melanoma — 2.
During routine dermatological examination, data con-
cerning phenotypic features such as skin phototype accord-
ing to Fitzpatrick [37], eye and hair color and total nevus
count were collected.
Skin phototype II was classified as ‘fair’ and III, IV —
as ‘dark’. There were no patients with I, V or VI photo-
types. Hair color was classified as fair hair (blond(e), red,
light brown) or dark hair (dark brown, black). Eye color
was also divided into two groups: fair eyes (blue, green) and
dark eyes (brown, black).
The total nevus count was divided into three groups:
< 20 nevi (low nevus count); 21–100 nevi (moderate nevus
count); and > 100 nevi (high nevus count).
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Patients also filled out a questionnaire [38] which contained
questions concerning their personal and/or family melanoma
history, and personal history of nonmelanoma skin cancer.
Histopathology and immunohistochemistry. The excised
samples were fixed in 10% buffered formalin and embed-
ded in paraffin. All lesions were evaluated using the stan-
dard histopathological criteria (hematoxylin and eosin-
stained 6 µm sections). The histological identification of
dysplastic nevi was based on the presence of junctional nests
of melanocytes often exhibiting large pleomorphic nuclei
and prominent nucleoli, uniformly elongated rete ridges and
lymphocytic infiltrations [39].
For each melanoma sample, tumor thickness, ulceration,
regression and mitotic rate were evaluated. Tumor thick-
ness was classified as thin (< 1 mm) or thick (≥ 1 mm).
Ulceration (area devoid of epidermis) was coded as 0 — ab-
sent, or 1 — present. The histological features of regression
included reduction in melanocyte density, as well as fibrosis
often accompanied by prominent small vessels and lympho-
cytic infiltration [40]. Regression was coded as 0 — absent,
or 1 — present. The mitotic rate (MR) was estimated in
a 1-mm ˛area, by beginning in the field with the highest
numbers of mitoses and then by counting in subsequent non-
overlapping fields, as recommended by the 1982 Pathology
Workshop [41, 42]. Due to the heterogeneity of our mela-
noma group (regarding differences in the number of mitot-
ic figures per 1 mm˛ between cases) we decided to code
MR as 0 — no mitoses or 1 — mitoses present [43].
For immunohistochemistry, deparaffinized 6 µm sections
were subjected to antigen retrieval in 10 mM citrate buffer,
pH 6.0 (5 min preincubation followed by 9 min in micro-
wave oven, 160 W, at 100°C, and 30 minutes in a vapor-bath
at 80°C). Next, the sections were incubated overnight at 4°C
with primary mouse antibodies against cyclin A or E (NCL
Cyclin A, NCL cyclin E, Novocastra Laboratories Ltd., New-
castle, UK, dilution 1:50 and 1:40, respectively), followed
by secondary goat anti-mouse Cy3-conjugated antibody
(Jackson IR, West Grove, PA, USA, code no. 115-165-146,
dilution 1:400). Cell nuclei were counterstained with DAPI
(Sigma, St Louis, MO, USA). Only nuclear immunostain-
ing was scored as positive. In each sample, cyclin expres-
sion was assessed as percentage of cyclin-positive nuclei in
the examined lesion. Microscopic examination, digital im-
aging of sections and image analysis were carried out using
an Olympus BX-50 bright field/epifluorescence microscope
equipped with DP-71 camera (Olympus, Japan) and
PC-based image analysis software (AnalySIS-FIVE®, Soft
Imaging System GmbH, Münster, Germany).
Statistical analysis. The relationship between expression
of cyclins, the type of melanocytic skin lesion (common nevi,
dysplastic nevi, melanoma) and other features was evaluat-
ed by nonparametric ANOVA rank Kruskal–Wallis plus post-
-hoc and Mann–Whitney tests, with p < 0.05 as the condi-
tion for statistical significance. For analysis of qualitative
parameters, contingency tables with Pearson’s chi-square
test for independence were used.
Results
All investigated lesion samples showed expression of
both cyclins; immunostaining was mostly observed in
cell nuclei (Figure 1), with some cells also exhibiting
weak cytoplasmic staining. In all types of melanocyt-
ic lesions (common nevi, dysplastic nevi and melano-
ma), the distribution of cyclin-positive cells was uni-
form. In normal skin (healthy margins of the excised
lesions), the expression of cyclins A and E was not
detected.
Statistically significant differences in the expres-
sion of both cyclins were observed between all skin
lesion types (p < 0.001, Figure 2). The median per-
centage of cyclin A-positive nuclei was 8.2% in mela-
nomas, 3.4% in dysplastic nevi and 0.95% in com-
mon nevi, with differences between melanomas and
both dysplastic and common nevi statistically signifi-
cant at p < 0.001, and between dysplastic and com-
mon nevi at p = 0.045. The corresponding percent-
ages for cyclin E were 9.5%, 4.25% and 1.44%, with
differences between melanomas and dysplastic nevi
significant at p = 0.02, between melanomas and com-
mon nevi at p < 0.001, and between dysplastic and
common nevi at p = 0.008.
In the melanoma group, there were 11 cases
(32.35%) of thin melanoma (< 1 mm) and 21 cases
(61.76%) of thick melanoma (≥ 1 mm including 3 cases
> 4 mm); in two cases (LM, SSM in situ) the Breslow
scale was not counted. However, no significant correla-
tions were observed between cyclin expression and tu-
mor thickness. No significant differences in cyclin A and
E scores were found either in melanoma group patients
with ulceration or regression presented in histopatho-
logical examination, or in relation to mitotic rate.
Statistically significant differences (p < 0.001) were
observed between all groups (melanoma, common nevi
and dysplastic nevi) in total nevus count. The largest
high TNC proportion (65%) and the smallest low TNC
proportion (0%) were demonstrated in the melanoma
group. Differences in cyclin A expression were statisti-
cally significant between patients with high TNC com-
pared to moderate and low TNC (8.15% vs. 5.76% vs.
3.98%, p=0.0056). Differences in cyclin E expression
did not show significance (Figure 3).
No significant correlations were found between
cyclin A and E expression and such phenotypic fea-
tures as hair color, eye color or skin phototype, nei-
ther in the whole group, nor in any separately investi-
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gated group with the particular type of melanocytic
skin lesion.
For the whole investigated population of patients,
we checked a possible relationship between cyclin
A and E expression and personal or family melano-
ma history, as well as personal history of NMSC. Ex-
pression of both cyclins was significantly higher only
among patients with a personal history of NMSC
(Figure 4).
Discussion
In our study, all investigated lesion samples showed
expression of both cyclins, with statistically signifi-
cant differences between melanomas and dysplas-
tic nevi, between melanomas and common nevi, and
between dysplastic and common nevi. Both cyclins
revealed significantly lower expression in dysplas-
tic nevi than in melanomas, but higher than in com-
mon nevi.
A similar pattern was observed by us in the case
of cyclin D3 [26] and we suggest that it could serve as
a suitable diagnostic marker for differentiation of
these lesions in histologically uncertain cases. Wheth-
er the same can be postulated for cyclins A and E sep-
arately is rather doubtful, since the level of significance
is lower, although the study was carried out on a larger
number of lesion samples. However, a joint examina-
tion of the three cyclins could provide a useful and more
reliable diagnostic approach in such cases.
Figure 1. Representative micrographs showing exemplary cyclin immunostaining in melanocytic skin lesions:
cyclin A-positive nuclei (red) in common nevus (A), dysplastic nevus (B) and melanoma (C). Nuclei counterstained
by DAPI (blue). Scale bar = 100 µm
Figure 2. Cyclin A and E expression in three types of
melanocytic skin lesion. Asterisk: significantly different
(p < 0.05) from dysplastic nevi and common nevi; double
asterisk: significantly different from melanoma and
common nevi
Figure 3. Correlation between cyclin A and E expression
and total nevus count (low: < 20 nevi; moderate: 21–100
nevi; high: > 100 nevi). Asterisk: significantly different
(p < 0.05) from moderate and low total nevus count
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There is no available data about cyclin A and cy-
clin E expression in dysplastic nevi in comparison with
melanoma. In our study, melanomas showed signifi-
cantly higher expression of cyclins A and E compared
to dysplastic nevi. That latter group of melanocytic
lesions still remains a potentially challenging diagnos-
tic problem for the pathologist because of its histo-
logical similarities with some melanomas. In the stud-
ies comparing expression of cyclins in melanocytic nevi
and melanomas, dysplastic nevi were usually not in-
cluded in the analysis as a separate group. In ambig-
uous cases, an additional marker is needed to improve
diagnostic accuracy [44]. Cyclins examined in this
study seem to be potential candidates.
‘Fair’ hair, eyes and skin (Fitzpatrick phototype I,
II) are the characteristic phenotypic features of a ‘typ-
ical’ patient with melanoma [45]. In patients exam-
ined in this study, a significant predominance of fair
hair was observed in all groups, and of fair skin in
melanoma patients, while no significance was found
for the occurrence of fair/dark eyes. There were, how-
ever, no significant correlations between cyclin A and
E expression and these phenotypic features.
It has been demonstrated that total nevus count
and the count of dysplastic nevi positively correlates
with melanoma risk [45, 46]. The expression of cy-
clin A (but not E) was significantly higher in patients
with high total nevus count compared to those with
moderate and low total nevus count, suggesting that
cyclin A might be involved in the formation of mul-
tiple nevi.
Several clinical and histological parameters influ-
ence melanoma prognosis. Of these, the most impor-
tant for primary tumors are tumor thickness (Breslow
scale), mitotic rate and the presence of ulceration or
regression. In problematic cases, these parameters are
not always sufficient and additional data is needed to
clarify the prognosis [43, 44, 47].
In the melanoma group, there was no correlation
between cyclin A and E expression and tumor thick-
ness, irrespective of tumor type. Other authors, how-
ever, have reported such a correlation. Flørenes et al.
[35] who investigated cyclin A expression in 172 pri-
mary, 73 metastatic melanomas and ten benign nevi
found tumor thickness to be the strongest prognostic
marker and cyclin A to be an independent prognostic
predictor of relapse-free survival. Similar results were
demonstrated by Tran et al. [33], who found a statisti-
cally significant correlation between expression of
cyclin A and tumor thickness and mitotic index.
In this study, there was no statistically significant
correlation of cyclin A and E expression with mitotic
rate. This is quite surprising, and might be due to
a relative scarcity of mitotic figures in our material.
As we did not show statistically significant differ-
ences in cyclin A and cyclin E expression among mel-
anoma group patients with or without ulceration or
regression presented in histopathological examina-
tion, the studied cyclins do not seem to have any prog-
nostic significance in this context. Accordingly, nei-
ther ulceration nor the location of primary tumors
had an impact as a prognostic factor in the study of
Florenes et al. [35].
A patient with a personal history of melanoma is
clearly at greater risk for subsequent melanoma. For
melanoma patients with a positive family history, the
risk for a second primary melanoma increases to 19%
[45]. Among our patients, only five had a personal,
and six a family, melanoma history. So, because of
the low number of such cases, the absence of signifi-
cant differences in cyclin A and E expression in rela-
tion to melanoma history should not be regarded as
proven, especially since expression of both cyclins was
significantly higher among patients with a personal
history of NMSC.
In summary, the present study has shown overex-
pression of cyclins A and E in melanoma compared
to dysplastic and common nevi. A positive correla-
tion between those cyclins’ immunoreactivity and
some clinical parameters of melanoma implicates
their role in the pathogenesis of this neoplasm. Our
findings also indicate a potential diagnostic signifi-
cance of cyclins A and E as proliferation markers in
melanocytic lesions.
Figure 4. Correlation between cyclin A and E expression
and personal history of nonmelanoma skin cancer
(NMSC). Asterisk: significantly different (p < 0.05) from
the group with no NMSC history
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